1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Exelixis, Inc.
  6. News
  7. Summary
    EXEL   US30161Q1040

EXELIXIS, INC.

(EXEL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EXELIXIS, INC. : Results of Operations and Financial Condition (form 8-K)

01/10/2022 | 04:32pm EDT

Item 2.02 Results of Operations and Financial Condition.


On January 9, 2022, Exelixis, Inc. ("Exelixis") issued a press release
announcing its preliminary unaudited financial results for the quarter and full
year ended December 31, 2021, providing financial guidance for the full year
ending December 30, 2022, and delivered an update on its business. A copy of
such press release is furnished herewith as Exhibit 99.1 and is incorporated
herein by reference. The preliminary unaudited financial results contained in
the press release do not present all information for an understanding of
Exelixis' financial condition as of December 31, 2021 and its results of
operations for the quarter and year ended December 31, 2021. The audit of
Exelixis' financial statements for the year ended December 31, 2021 is ongoing
and could result in changes to the information in the press release. The press
release also announced that Exelixis will report its complete audited financial
results for the quarter and full year ended December 31, 2021 on February 17,
2022.

The information in this report, including the exhibit hereto, shall not be
deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934, as amended, or otherwise subject to the liabilities of that section or
Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The
information contained in this report and in the accompanying exhibit shall not
be incorporated by reference into any filing with the U.S. Securities and
Exchange Commission made by Exelixis, whether made before or after the date
hereof, regardless of any general incorporation language in such filing.
.
Item 9.01 Financial Statements and Exhibits.

(d)   Exhibits.
  Exhibit Number               Exhibit Description
       99.1                 Press Release Dated January
                          9, 2022

        104               Cover Page Interactive Data          The cover

page interactive data file does not appear

                          File                                 in the 

Interactive Data File because its XBRL tags

                                                               are embedded 

within the Inline XBRL document.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

All news about EXELIXIS, INC.
05/27EXELIXIS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vot..
AQ
05/26Exelixis Details Results of Two Cancer Trials of Cabozantinib in Combination With Pembr..
MT
05/26Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung C..
BU
05/26Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembr..
BU
05/26Exelixis, Inc. Announces Results from Phase 2 Trial of Cabozantinib in Combination with..
CI
05/17TRANSCRIPT : Exelixis, Inc. Presents at RBC Capital Markets Global Healthcare Conference, ..
CI
05/11TRANSCRIPT : Exelixis, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11..
CI
05/10TRANSCRIPT : Exelixis, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/10Exelixis Q1 Non-GAAP EPS, Revenue Higher; Reiterates 2022 Guidance
MT
05/10EXELIXIS : Q1 Earnings Snapshot
AQ
More news
Analyst Recommendations on EXELIXIS, INC.
More recommendations